These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

732 related articles for article (PubMed ID: 35431535)

  • 21. Alpha to Omicron (Variants of Concern): Mutation Journey, Vaccines, and Therapy.
    Hamad M; AlKhamach DMH; Alsayadi LM; Sarhan SA; Saeed BQ; Sokovic M; Ben Hadda T; Soliman SSM
    Viral Immunol; 2023 Mar; 36(2):83-100. PubMed ID: 36695729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
    Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
    Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges.
    Malik JA; Ahmed S; Mir A; Shinde M; Bender O; Alshammari F; Ansari M; Anwar S
    J Infect Public Health; 2022 Feb; 15(2):228-240. PubMed ID: 35042059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
    Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
    mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Scope of SARS-CoV-2 variants, mutations, and vaccine technologies.
    Wambani J; Okoth P
    Egypt J Intern Med; 2022; 34(1):34. PubMed ID: 35368846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alum/CpG Adjuvanted Inactivated COVID-19 Vaccine with Protective Efficacy against SARS-CoV-2 and Variants.
    Zhang Y; Zheng X; Sheng W; Liang H; Zhao Y; Zhu X; Yang R; Zhang Y; Dong X; Li W; Pei F; Ding L; Chang Z; Deng L; Yuan G; Yang Z; Zhu D; Yang X; Wang H
    Vaccines (Basel); 2022 Jul; 10(8):. PubMed ID: 36016098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world.
    Chavda VP; Yao Q; Vora LK; Apostolopoulos V; Patel CA; Bezbaruah R; Patel AB; Chen ZS
    Front Immunol; 2022; 13():961198. PubMed ID: 36263030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How do the severe acute respiratory coronavirus 2 (SARS-CoV-2) and its variants escape the host protective immunity and mediate pathogenesis?
    Noor R
    Bull Natl Res Cent; 2022; 46(1):255. PubMed ID: 36254244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of antibody resistance in emerging mutant strains of SARS CoV-2: Impediment for COVID-19 vaccines.
    Beeraka NM; Sukocheva OA; Lukina E; Liu J; Fan R
    Rev Med Virol; 2022 Sep; 32(5):e2346. PubMed ID: 35416390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Review on the Effectivity of the Current COVID-19 Drugs and Vaccines: Are They Really Working Against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants?
    Noor R
    Curr Clin Microbiol Rep; 2021; 8(3):186-193. PubMed ID: 34249605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants.
    Liu C; Rcheulishvili N; Shen Z; Papukashvili D; Xie F; Wang Z; Wang X; He Y; Wang PG
    Pharmaceutics; 2022 May; 14(5):. PubMed ID: 35631687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on omicron variant: What we know so far.
    Choudhary G; Prajapat M; Kumaravel J; Prabha PK; Sarma P; Handa V; Kaur H; Patel AP; Medhi B
    Indian J Pharmacol; 2022; 54(1):41-45. PubMed ID: 35343206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A tabulated summary of the evidence on humoral and cellular responses to the SARS-CoV-2 Omicron VOC, as well as vaccine efficacy against this variant.
    Minka SO; Minka FH
    Immunol Lett; 2022 Mar; 243():38-43. PubMed ID: 35131373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera.
    Hu J; Wei XY; Xiang J; Peng P; Xu FL; Wu K; Luo FY; Jin AS; Fang L; Liu BZ; Wang K; Tang N; Huang AL
    Genes Dis; 2022 Sep; 9(5):1290-1300. PubMed ID: 34877393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant.
    Khong KW; Liu D; Leung KY; Lu L; Lam HY; Chen L; Chan PC; Lam HM; Xie X; Zhang R; Fan Y; To KK; Chen H; Yuen KY; Chan KH; Hung IF
    Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Development of SARS-CoV-2 Variants: The Gene Makes the Disease.
    Perez-Gomez R
    J Dev Biol; 2021 Dec; 9(4):. PubMed ID: 34940505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Homologous and Heterologous Vaccine Boosters With SARS-CoV-2 Infection in BBIBP-CorV Vaccinated Healthcare Personnel.
    Park S; Gatchalian KK; Oh H
    Cureus; 2022 Jul; 14(7):e27323. PubMed ID: 36043010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular and Epidemiological Characterization of Emerging Immune-Escape Variants of SARS-CoV-2.
    Miyakawa K; Jeremiah SS; Yamaoka Y; Koyama T; Tokumasu R; Kudo M; Kato H; Ryo A
    Front Med (Lausanne); 2022; 9():811004. PubMed ID: 35223905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.